Top Medical News
Yesterday
Global hypomethylation of Alu appears to increasingly influence distant metastatic differentiated thyroid cancer (DTC), poorly (P)DTC and anaplastic (A)TC, according to a recent study. This suggests that the epigenetic entity may be involved in thyroid cancer progression and dedifferentiation.
Yesterday
Cessation advice based on the communication of risks appears to be ineffective in getting cancer patients to quit smoking, a recent study has shown. On the other hand, the approach seems to improve smoking reduction.
Tristan Manalac, 2 days ago
Placebo pills, even when administered open-label, appear to significantly improve cancer-related fatigue and fatigue-disrupted quality of life, according to a recent study.
3 days ago
New drug applications approved by US FDA as of 1 - 15 February 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
4 days ago
Depressive symptoms persist months after radical prostatectomy in nearly one of three men surgically treated for prostate cancer, with patients who undergo open radical prostatectomy reporting higher depressive symptoms than those treated with robot-assisted radical prostatectomy, according to a recent study.
Christina Lau, 5 days ago

Combining gabapentin or pregabalin with opioid analgesics does not significantly improve cancer pain relief compared with opioid monotherapy, according to results of a recent systematic review and meta-analysis.

Pank Jit Sin, 5 days ago

In a bid to improve patients’ access to cancer medicines, Bayer Co. (Malaysia) recently launched an online web app. The launch coincided with World Cancer Day in February.

Special Reports
29 Jan 2018

Role of comprehensive genomic profiling in personalized treatment

22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
04 Dec 2017
Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.
Dr Joslyn Ngu, 04 Dec 2017

Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.

Dr Joslyn Ngu, 04 Dec 2017

Incorporating polygenic risk scores based on 18 SNPs (single nucleotide polymorphisms) into risk stratification for breast cancer will improve screening results, says an expert.

Dr Joslyn Ngu, 04 Dec 2017

Making genetic testing mainstream, allows more patients to be tested, identifies more carriers and enables appropriate stratification of treatment and outcomes, says an expert.

Dr Joslyn Ngu, 04 Dec 2017

Hereditary breast and ovarian cancer (HBOC) syndrome, which is primarily caused by BRCA1 and BRCA2 mutations, make up 8 to 10 percent of all breast cancers, says a senior consultant.

Conference Reports
Christina Lau, 12 Feb 2018
Chinese patients with metastatic castration-resistant prostate cancer (mCRPC) have higher response rates, longer survival and a lower risk of fatigue when enzalutamide is used in earlier rather than later lines of treatment, a study by the Hong Kong Society of Uro-Oncology has shown.
Christina Lau, 07 Feb 2018
Adding docetaxel to androgen deprivation therapy (ADT) can prevent prostate-specific antigen (PSA) progression and delay the development of castration resistance in Chinese patients with metastatic hormone-naïve prostate cancer, a study by the Chinese University of Hong Kong (CUHK) has shown.
Roshini Claire Anthony, 06 Feb 2018

The combination of nivolumab and ipilimumab demonstrated strong response, progression-free survival (PFS), and overall survival (OS) rates in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic or recurrent colorectal cancer (CRC), results from the phase II CheckMate-142* trial show.

Roshini Claire Anthony, 30 Jan 2018

The addition of ramucirumab, a fully human IgG1 monoclonal antibody receptor antagonist, to chemotherapy, prolonged progression-free survival (PFS) in individuals with previously untreated metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma, findings from the phase III RAINFALL* trial show. 

Dr. Joseph Delano Fule Robles, 29 Jan 2018

Findings of recently completed trials have shown that atezolizumab and pembrolizumab could be possible first-line therapy options for cisplatin-ineligible patients with advanced and metastatic urothelial carcinoma, according to a presentation at the Hong Kong Society of Uro-Oncology Annual Scientific Meeting 2018. 

22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Elvira Manzano, Roshini Claire Anthony, 18 Jan 2018
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD